Adalvo is excited to announce the introduction of Apalutamide to our Oncology Portfolio.
Based on the reference brand Erleada, Apalutamide, available in film-coated tablet form with strengths of 60mg and 240mg, is a treatment option for adults facing non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC).
Apalutamide has impacted the pharmaceutical market, with a total IQVIA MAT sale of $3 billion in 2023 and a 3Y CAGR of 30%.
Adalvo is committed to a timely submission and Day 1 launch in major markets, with a clearly defined product pathway.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner up now!